Ignite Creation Date:
2024-05-06 @ 3:54 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04790474
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-04-21
First Post:
2021-03-07
Brief Title:
Ixazomib-pomalidomide-dexamethasone As Second or Third-line Combination Treatment for Patients with Relapsed and Refractory Multiple Myeloma Previously Treated with Daratumumab Lenalidomide and Bortezomib
Sponsor:
Tel-Aviv Sourasky Medical Center
Organization:
Tel-Aviv Sourasky Medical Center
Organization Data
Organization:
Tel-Aviv Sourasky Medical Center
Class:
OTHER_GOV
Study ID:
0776-19-TLV
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None